MA48461A - Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation - Google Patents

Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Info

Publication number
MA48461A
MA48461A MA048461A MA48461A MA48461A MA 48461 A MA48461 A MA 48461A MA 048461 A MA048461 A MA 048461A MA 48461 A MA48461 A MA 48461A MA 48461 A MA48461 A MA 48461A
Authority
MA
Morocco
Prior art keywords
excipients
viscosity
reduce
antibody formulations
formulation compositions
Prior art date
Application number
MA048461A
Other languages
English (en)
Inventor
Robert Matthew Fesinmeyer
Jian Hua Gu
Rulin Qian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48461A publication Critical patent/MA48461A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
MA048461A 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation MA48461A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492049P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
MA48461A true MA48461A (fr) 2020-03-04

Family

ID=62148500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048461A MA48461A (fr) 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Country Status (4)

Country Link
US (1) US20200352857A1 (fr)
EP (1) EP3615065A1 (fr)
MA (1) MA48461A (fr)
WO (1) WO2018200533A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109439536A (zh) * 2017-08-18 2019-03-08 黄国仁 饮用水细菌快速培养装置及菌落总数快速检测系统
US20220275073A1 (en) * 2019-08-12 2022-09-01 Amgen Inc. Anti-Sclerostin Antibody Formulations
BR112022016456A2 (pt) * 2020-02-18 2022-10-04 Amgen Inc Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
CA3187322A1 (fr) * 2020-07-13 2022-01-20 Merck Patent Gmbh Excipients reducteurs de viscosite et leurs combinaisons pour formulations de proteines hautement concentrees
WO2023140807A1 (fr) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de trastuzumab

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
CA2050918A1 (fr) 1990-01-12 1991-07-13 Raju Kucherlapati Production d'anticorps xenogeniques
WO2004039337A2 (fr) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Formulations pharmaceutiques liquides stables d'anticorps ayant tendance a l'isomerisation
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
CN102958538A (zh) * 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
KR101673654B1 (ko) * 2011-04-20 2016-11-07 산도즈 아게 융합 단백질 TNFR:Fc의 안정한 제약 액체 제제
BR112014010186A2 (pt) 2011-10-28 2017-05-02 Integritybio Inc formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
SG10201806539XA (en) * 2013-09-11 2018-08-30 Eagle Biologics Inc Liquid protein formulations containing ionic liquids
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3169710A1 (fr) * 2014-07-14 2017-05-24 Amgen Inc. Formulations d'anticorps cristallins
MX2017005243A (es) 2014-10-23 2017-08-18 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas.

Also Published As

Publication number Publication date
US20200352857A1 (en) 2020-11-12
EP3615065A1 (fr) 2020-03-04
WO2018200533A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
MA48461A (fr) Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
MA49043A (fr) Formulation stable d'anticorps
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA51873A (fr) Molécules probiotiques pour réduire la virulence d'agents pathogènes
MA49253A (fr) Compositions solides pour administration orale
MA54139A (fr) Formulation d'anticorps
MA54052A (fr) Formulation d'anticorps
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MA51903A (fr) Formulations d'anticorps b7-h4
MA43361A (fr) Composition pour le soin et la protection de cultures
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA53466A (fr) Formulation stable d'anticorps anti-osmr
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MX2019008544A (es) Nueva formulacion estable para anticuerpos anti-fxia.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
MA50670A (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression